Does BPC-157 cause cancer? What the research shows

Last updated 2026-07-23

Does BPC-157 cause cancer, based on current research?

No study, animal or human, has reported that BPC-157 causes cancer. That's the honest starting point, and it cuts both ways: the absence of a cancer signal isn't the same as proof of safety, because nobody has run the kind of long-term carcinogenicity study that would actually answer the question. Most of what exists is preclinical, meaning rodent and cell-culture work looking at wound healing, tendon repair, gut protection, and blood vessel formation. A 2025 literature and patent review in Pharmaceuticals covering the broader BPC-157 research base describes its proposed mechanisms across multiple organ systems, but the paper is a review of existing mechanistic and patent literature, not a cancer-specific safety study ^[1]. A 2025 narrative review titled "Regeneration or Risk?" explicitly frames the open question in its title: does a peptide that promotes angiogenesis and tissue growth carry a theoretical risk profile that needs more scrutiny before wide human use ^[2]. That review doesn't conclude BPC-157 causes cancer. It concludes the safety data needed to rule the concern out definitively isn't there yet. So the real answer is: no cancer signal has shown up in the literature so far, but the literature is thin, mostly animal-based, and not designed to detect rare or long-latency events like tumor formation.

Why do people worry BPC-157 might be linked to cancer?

The concern comes from mechanism, not from any actual finding. BPC-157 is studied for its effects on angiogenesis, the process of forming new blood vessels, because that's part of how it's proposed to speed healing in tendons, ligaments, muscle, and gut lining ^[3][4]. Angiogenesis is also a process tumors depend on to grow past a certain size. That overlap is where the worry starts. A 2014 paper in Current Pharmaceutical Design specifically reviewed BPC-157's relationship to blood vessels, describing it as promoting vessel formation in injury and ischemia models ^[5]. That's a rodent and tissue-model finding about healing, not a finding about tumor promotion. But it's easy to see why someone reading "promotes new blood vessel growth" jumps to "could feed a tumor." It's a fair theoretical question. It hasn't been tested directly as far as the published record shows. The 2025 orthopaedic systematic review in HSS Journal, which pooled the sports medicine and musculoskeletal literature on BPC-157, likewise reports healing-related outcomes (tendon, ligament, muscle) without describing any oncogenic findings in the studies it reviewed ^[6]. Absence of a reported problem in a review of this size is reassuring as far as it goes, but a systematic review of injury-healing studies isn't a cancer surveillance study either.

Has any BPC-157 study looked specifically at cancer risk?

Not directly, no. There is no dedicated carcinogenicity study of BPC-157 in the published record reviewed here, and none of the human pilot studies were designed or powered to detect cancer risk. The two human studies in this evidence base are small and outcome-specific. One is a 2021 study on intra-articular BPC-157 injection for knee pain, published in Alternative Therapies in Health and Medicine ^[7]. The other is a 2024 pilot study on BPC-157 for interstitial cystitis symptoms, in the same journal ^[8]. Both are small, early-phase clinical studies looking at symptom relief and function, not cancer surveillance trials. Neither reported cancer as an outcome measure, and neither would be large enough or long enough in follow-up to catch a rare or slow-developing cancer risk even if one existed. That's the honest gap: nobody has run the years-long, large-cohort study needed to answer "does this substance change cancer incidence." Until that kind of trial exists, the question is unanswered rather than answered-in-the-negative.

What does the animal research actually show BPC-157 doing?

The bulk of BPC-157 data comes from rodent models, and it's worth being precise about what those models tested. A 2019 paper in Cell and Tissue Research describes BPC-157's role in accelerating musculoskeletal soft tissue healing in animal models, covering tendon and ligament repair mechanisms ^[4]. A 2011 study in the Journal of Applied Physiology found that BPC-157 promoted tendon healing in a rat model through tendon outgrowth, cell survival, and cell migration ^[9]. A 2018 review in Current Pharmaceutical Design compared BPC-157's effects to standard angiogenic growth factors across gut, tendon, ligament, muscle, and bone healing models ^[3]. These are legitimate, specific findings, but they are animal findings about repair processes, not human outcomes and not cancer studies. Cell survival, migration, and new vessel growth are exactly the processes involved in normal wound healing. They're also processes that, in a different context (an existing tumor, for instance), could theoretically support unwanted growth. No published study has tested BPC-157 in an animal cancer model to see whether it accelerates tumor growth or metastasis. That's a real, specific hole in the literature, not a hidden finding of harm. Dose levels used in these animal studies are also not something a person should translate into a human dosing plan. Rodent µg/kg dosing in a controlled lab setting doesn't map cleanly onto human dosing, and none of these papers were designed to establish a safe human dose.

What do the newer clinical and orthopaedic reviews say about safety?

Several 2025 and 2026 reviews aimed at orthopaedic and sports medicine physicians have started grappling with BPC-157's safety profile directly, largely because patients are already asking about it and some are self-sourcing it outside of medical supervision. A 2026 paper in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews looks at therapeutic peptides in orthopaedics broadly, covering applications, challenges, and what still needs to happen before these compounds could be considered standard care ^[10]. A 2026 primer in the American Journal of Sports Medicine walks physicians through injectable peptide therapy, again treating BPC-157 as part of an emerging, not established, treatment category ^[11]. A 2025 paper in Arthroscopy asks directly whether injectable therapeutic peptides are a real adjunct to regenerative medicine and sports performance or getting ahead of the evidence ^[12]. A 2026 safety and efficacy review in Sports Medicine looked specifically at approved versus unapproved peptide therapies used for musculoskeletal injury and athletic performance, a useful framing because it separates products with real regulatory review from those without one ^[13]. None of these reviews report a cancer signal for BPC-157. Each of them, in one way or another, flags that long-term human safety data, cancer risk included, is not yet established. That's a consistent theme across the newest literature: promising mechanism, thin long-term human safety record.

Is BPC-157 FDA-approved, and does that affect the cancer question?

No. BPC-157 is not an FDA-approved drug. It does not appear in the Drugs@FDA database of approved drug products ^[14], which means it has never gone through the clinical trial process the FDA requires to establish safety and efficacy for any indication, including long-term cancer risk. That regulatory status matters directly here. Approved drugs go through Phase 1 through Phase 3 trials and post-market surveillance that specifically screen for adverse events over time, cancer included. BPC-157 has not been through that process. It's also not on the FDA's current list of bulk drug substances that can be used in 503A compounding [see 21 CFR 216.23, the 503A Bulks List] or the 503B Bulks List for outsourcing facilities [21 CFR 216.24], and the FDA's nominated substances list shows it under review rather than accepted ^[15][16][17]. The practical upshot: nobody has run the kind of regulator-mandated, long-term safety trial that would give a clean answer on cancer risk, because BPC-157 hasn't gone through that pathway. That's different from saying the pathway was tried and BPC-157 failed a cancer safety check. It hasn't been tested that way at all.

What does BPC-157's known mechanism suggest about tumor growth, in theory?

Mechanistically, the honest picture is mixed and unresolved, which is exactly why reviewers keep raising the question rather than closing it. BPC-157 is proposed to work partly through promoting angiogenesis, the growth of new blood vessels, a process documented in the 2014 Current Pharmaceutical Design review ^[5] and referenced again in the broader mechanism review in the 2025 Pharmaceuticals literature review ^[1]. Tumors need blood supply to grow past a small size, so anything that promotes vessel growth is worth scrutinizing in that context. On the other side, BPC-157 is also studied for anti-inflammatory and cytoprotective effects, and chronic inflammation is itself a recognized contributor to some cancers, so a genuinely anti-inflammatory compound could theoretically cut a different kind of risk. Both of those are theoretical arguments built from mechanism, not real findings from a cancer study. The 2025 "Regeneration or Risk?" review is useful precisely because its title captures this tension honestly instead of resolving it one way or the other ^[2]. Until someone runs a dedicated tumor model study or a large long-term human cohort, this stays a theoretical discussion, not a documented risk or a documented protection.

Should people with a history of cancer avoid BPC-157?

There's no data one way or the other, which is itself the reason for caution. Because no cancer-specific safety study exists, and because the proposed angiogenic mechanism is at least theoretically relevant to tumor biology ^[5], anyone with a personal or strong family history of cancer, or anyone with an active or recently treated malignancy, should treat that as a real open question to raise with their oncologist or treating physician before considering BPC-157 for any use. This is a case where "no evidence of harm" and "evidence of no harm" are genuinely different things, and it matters which one you're relying on. The former is true here. The latter is not established. A provider who reviews someone's full history, including cancer history, is in a better position to weigh that theoretical mechanism against a person's actual risk profile than a self-directed purchase ever could be. That's part of why sourcing through a provider-reviewed route with pharmacy dispensing matters more for a compound like this than for a typical supplement.

What other side effects and safety signals does BPC-157 research report?

Outside the cancer question specifically, the safety picture from the small human studies is limited but not alarming so far. The 2021 knee pain study using intra-articular BPC-157 injection reported on symptom and function outcomes in patients with various knee conditions, without describing serious adverse events in that small sample ^[7]. The 2024 interstitial cystitis pilot study similarly reported on symptom improvement in a small patient group ^[8]. The broader safety literature, including the 2025 HSS Journal systematic review of BPC-157 in orthopaedic sports medicine ^[6] and the 2026 Sports Medicine review of approved versus unapproved peptide therapies ^[13], consistently flags the same limitation: small sample sizes, short follow-up windows, and a near-total reliance on animal data for mechanism and dosing. If you want the fuller rundown on documented and theoretical side effects, that's worth reading before considering any BPC-157 product, cancer risk aside. None of this adds up to "proven safe." It adds up to "no major red flag reported yet, in a research base too small and too short to catch anything but a common, fast-appearing problem."

How should this evidence gap shape a decision about using BPC-157?

Treat the cancer question as genuinely open, not answered in either direction. That's the responsible reading of a literature dominated by rodent tissue-repair studies ^[3][4][9], a couple of small human pilot trials on unrelated outcomes ^[7][8], and review articles that raise the theoretical angiogenesis question without resolving it ^[2][5]. A few practical things follow from that. First, don't treat a lack of reported cancer cases as proof of safety; the studies weren't built to find them. Second, don't treat the angiogenesis mechanism as proof of danger either; it's a real theoretical consideration, not a documented outcome. Third, this is exactly the kind of gray area where getting a compound through a provider who reviews personal and family medical history, rather than an unregulated online seller, is the more defensible route. If you're weighing where and how to source it, our BPC-157 for sale guide covers the regulatory landscape, and BPC-157 Co works with a licensed compounding pharmacy specifically so that a provider reviews someone's history before dispensing, rather than skipping that step entirely. If you're still building your basic understanding of what BPC-157 is and what the research covers, start with the BPC-157 peptide overview before getting into dosing or sourcing decisions.

Frequently asked questions

Does BPC-157 cause cancer in humans?

No published human study has found that BPC-157 causes cancer. But the human evidence base is very small (a knee pain study and an interstitial cystitis pilot study, both small and short) and neither was designed to detect cancer risk, so this remains an open question rather than a settled negative.

Does BPC-157 cause cancer in animal studies?

No animal study reviewed here reports BPC-157 causing cancer. The rodent literature focuses on tendon, ligament, muscle, and gut healing [PMID 30915550, PMID 21030672], not tumor models. Nobody has published a dedicated carcinogenicity study of BPC-157 in animals as of this writing.

Why do some people think BPC-157 could promote tumor growth?

Because BPC-157 is studied for promoting angiogenesis, new blood vessel formation, which is part of how it's proposed to speed healing [PMID 23782145]. Tumors also depend on angiogenesis to grow. That mechanistic overlap is a theoretical concern raised in recent reviews, not a documented finding of tumor promotion.

Is BPC-157 FDA approved?

No. BPC-157 does not appear in the FDA's Drugs@FDA database of approved products. It has not gone through FDA clinical trials, and it is not currently accepted on the 503A or 503B bulk drug substance lists used for pharmacy compounding, per the FDA's compounding guidance.

Has anyone studied BPC-157's long-term safety in humans?

No. The available human studies are small pilot trials with short follow-up: a 2021 knee pain injection study and a 2024 interstitial cystitis pilot study. Neither followed patients long enough or in numbers large enough to assess long-term risks, cancer included.

Should someone with a cancer history avoid BPC-157?

There's no direct data to answer this, which is itself a reason for caution. Given the theoretical angiogenesis mechanism, anyone with a personal or family cancer history should discuss BPC-157 with their treating physician or oncologist before considering it, rather than deciding alone.

What does BPC-157 actually do in the research, if not cause cancer?

The published record centers on tissue repair: tendon healing via cell migration and outgrowth in rat models [PMID 21030672], gut and musculoskeletal soft tissue healing [PMID 30915550], and wound healing mechanisms reviewed in Frontiers in Pharmacology [PMID 34267654]. These are healing-focused findings, mostly preclinical.

Do the newest 2025-2026 reviews flag cancer risk with BPC-157?

They flag it as an open theoretical question, not a documented finding. The 2025 review titled 'Regeneration or Risk?' explicitly names this tension in its title, and orthopaedic/sports medicine reviews from 2025-2026 consistently note that long-term human safety data, including cancer risk, isn't established yet.

Is BPC-157 safe to use at all, given the unknowns?

That depends on individual risk tolerance and medical history. The short-term human data hasn't shown alarming safety signals, but the evidence is thin, mostly animal-based, and not built to catch rare or long-latency risks. A provider-reviewed approach that accounts for personal history is the more cautious path.

What's the difference between 'no evidence BPC-157 causes cancer' and 'BPC-157 is proven not to cause cancer'?

They're not the same claim. 'No evidence' means the studies done so far haven't found a link, but those studies (mostly animal, some small human trials) weren't designed to detect cancer risk. 'Proven not to' would require a dedicated long-term carcinogenicity study, which doesn't exist yet.

Does BPC-157's effect on blood vessel growth mean it feeds tumors?

Not established. BPC-157 is studied for promoting angiogenesis in healing contexts (tendon, gut, ischemic tissue), a mechanism reviewed in Current Pharmaceutical Design in 2014. Whether that same mechanism would promote tumor growth in a person with an existing cancer has not been directly tested.

Where can I read about BPC-157 side effects beyond cancer risk?

Our side effects guide covers documented and theoretical risks from the current study record, including what the small human trials reported and what remains unknown from the animal literature. It's worth reading in full before considering any BPC-157 product.

Sources

1. Pharmaceuticals (Basel), 2025 (PMID 40005999): Literature and patent review describing BPC-157's proposed mechanisms across organ systems, without reporting carcinogenicity findings
2. Current Reviews in Musculoskeletal Medicine, 2025 (PMID 40789979): Narrative review framing the open theoretical question of regeneration versus risk with BPC-157 for musculoskeletal healing
3. Current Pharmaceutical Design, 2018 (PMID 29998800): Comparison of BPC-157 to standard angiogenic growth factors in gut, tendon, ligament, muscle, and bone healing models
4. Cell and Tissue Research, 2019 (PMID 30915550): BPC-157's role in accelerating musculoskeletal soft tissue healing in preclinical models
5. Current Pharmaceutical Design, 2014 (PMID 23782145): BPC-157's documented relationship to blood vessel formation (angiogenesis) in injury and ischemia models
6. HSS Journal, 2025 (PMID 40756949): Systematic review of BPC-157 in orthopaedic sports medicine reporting healing outcomes without oncogenic findings
7. Alternative Therapies in Health and Medicine, 2021 (PMID 34324435): Small human study of intra-articular BPC-157 injection for knee pain, reporting symptom/function outcomes
8. Alternative Therapies in Health and Medicine, 2024 (PMID 39325560): Small pilot study of BPC-157 for interstitial cystitis symptoms
9. Journal of Applied Physiology, 2011 (PMID 21030672): Rat model study finding BPC-157 promotes tendon healing through outgrowth, cell survival, and cell migration
10. JAAOS Global Research & Reviews, 2026 (PMID 41490200): Review of therapeutic peptides in orthopaedics covering applications, challenges, and future directions
11. American Journal of Sports Medicine, 2026 (PMID 41476424): Primer for orthopaedic and sports medicine physicians on injectable peptide therapy as an emerging category
12. Arthroscopy, 2025 (PMID 39265666): Review questioning whether injectable therapeutic peptides are established adjuncts to regenerative medicine and sports performance
13. Sports Medicine, 2026 (PMID 41966639): Safety and efficacy review comparing approved versus unapproved peptide therapies for musculoskeletal injury and athletic performance
14. FDA, Drugs@FDA database: BPC-157 does not appear as an FDA-approved drug product
15. eCFR, 21 CFR 216.23 (503A Bulks List): Federal list of bulk drug substances permitted for 503A pharmacy compounding
16. eCFR, 21 CFR 216.24 (503B Bulks List): Federal list of bulk drug substances permitted for 503B outsourcing facility compounding
17. FDA, bulk drug substances nominated for compounding use: FDA's current list showing substances nominated for compounding review, relevant to BPC-157's regulatory status